The DOI matches its Crossref record; the references it cites are not checked yet.
Chromogranin A is not a biomarker of mastocytosis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There are insufficient data to demonstrate the clinical utility of heparin, serotonin, neuropeptides, platelet-activating factor, and chromogranin A in the diagnosis of MCA and MCAS.
“However, there are insuf fi cient data to demonstrate their clinical utility in the diagnosis of MCA and MCAS.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [75]
In “To the Editor” (page unavailable), the authors recommend against using serum chromogranin A as a biomarker of mast cell disease, supporting that part of the claim. They also say no diagnostic criteria have been proposed for heparin, but do not assess its clinical utility; the copy does not address the diagnostic utility of serotonin, neuropeptides, or platelet-activating factor. (LLM, conf=0.86)
Experimental — accuracy not yet measuredCgA levels are not elevated in patients with mastocytosis.
“Thus, CgA levels are not elevated in patients with mastocytosis.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [75]
In “To the Editor” (page not supplied), the paper reports normal serum CgA levels in patients with pediatric and adult mastocytosis except those taking proton pump inhibitors (PPIs). The claim omits that exception: all PPI-treated patients in the study had elevated CgA. (LLM, conf=0.92)
Experimental — accuracy not yet measuredThe finding of elevated serum CgA in patients with mastocytosis using PPIs does not correlate with MC burden or activation.
“however, this fi nding does not correlate with MC burden or activation.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [75]
The use of proton pump inhibitors may be associated with elevated serum CgA in patients with mastocytosis.
“Moreover, the use of proton pump inhibitors may be associated with elevated serum CgA in patients with mastocytosis”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [75]
Serum levels of CgA have been reported to be fairly specific to MCs.
“For instance, serum levels of CgA have been reported to be fairly speci fi c to MCs”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [75]
Nonvalidated serologic markers used to detect MCA include chromogranin A, serotonin, and heparin.
“Nonvalidated serologic markers utilized to detect MCA22 include chromogranin A,23 serotonin, and heparin.”
From Mast cell activation syndrome: Current understanding and research needs (2024) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 15 · Cited by 10
Research works printed but not linked: 1
- Valent, 2017, Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts, Blood, 129, 1420, 10.1182/blood-2016-09-731893 · DOI
Metadata
- Authors
- Hanjra, P., Lee, C.-C. R., Maric, I., Carter, M., Olivera, A., Metcalfe, D. D., & Komarow, H. D.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Komarow, Hirsh D.
- Venue
- The Journal of Allergy and Clinical Immunology: In Practice
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 6
- Issue
- 2
- Pages
- 687-689.e4
- ISSN
- 2213-2198 (ISSN-L)
- PMC
- PMC5845814
- OpenAlex
- W2763312208
- Cited by
- 10
- References
- 15
- Citations by year
- 2025: 1 · 2024: 2 · 2021: 2 · 2019: 4 · 2018: 1
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Journal of Allergy and Clinical Immunology In Practice (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (Z01AI000249)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Hematology › Histiocytic Disorders and Treatments
- Keywords
- chromogranin A, mastocytosis, biomarkers, cutaneous mastocytosis, urticaria pigmentosa, systemic mastocytosis, mast cells, mastocytoma, diffuse cutaneous mastocytosis
- MeSH terms
- Adolescent, Adult, Aged, Cell Line, Child, Child, Preschool, Female, Gastrins, Humans, Male, Mastocytosis, Middle Aged, Biomarkers, Chromogranin A, Tryptases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
